Nereus Pharmaceuticals' NPI-0052 Named One of the Industry's Top Ten Unpartnered Oncology Drug Candidates
Posted on: Tuesday, 16 October 2007, 09:00 CDT
SAN DIEGO, Oct. 16 /PRNewswire/ -- Nereus Pharmaceuticals, Inc., a pioneer in the use of marine microbial sources for the discovery and development of cancer therapeutics, today announced that one of its two lead drug candidates, NPI-0052, will be featured as a Top Ten Unpartnered Program at Windhover Information's 2nd Annual Therapeutic Area Partnerships conference taking place October 24-26, 2007 in Philadelphia, PA. Charles White, Ph.D., Chief Business Officer of Nereus, will provide an overview of the compound's mechanism, the ongoing Phase I clinical program, relative advantages identified in preclinical studies, and potential for broad adoption across solid tumors and hematological malignancies.
Nereus' novel, small molecule proteasome inhibitor NPI-0052 is in three Phase I trials for solid tumors, lymphomas, leukemias and multiple myeloma. Preclinical studies indicate that this next generation compound may be superior to Velcade(R), with broader target inhibition, faster onset and longer duration of action, higher potency, oral and intravenous availability, and activity against myeloma cells resistant to Velcade(R) (bortezomib, Millennium), Thalomid(R) (thalidomide, Celgene Corporation), Revlimid(R) (lenalidomide, Celgene Corporation) and steroid therapy. NPI-0052 was derived from a marine-obligate gram-positive actinomycete (Salinispora tropica).
NPI-0052 is being tested at world-class cancer centers in three Phase I clinical trials with sites in the U.S., Australia and Europe. Clinical trial sites include the M.D. Anderson Cancer Center, the Memorial Sloan-Kettering Cancer Center, the Dana-Farber Cancer Institute, Ohio State University, Roswell Park Cancer Institute and University of Chicago.
"Nereus' NPI-0052 is a highly differentiated product candidate that continues to attract interest because of the early positive signals we've seen in multiple cancer indications. We're pleased the NPI-0052 program will be featured at the Windhover conference, where we are eager to broaden its exposure to an international audience seeking promising partnering opportunities," said Kobi M. Sethna, President and CEO of Nereus Pharmaceuticals, Inc.
Windhover Information's 2nd Annual Therapeutic Area Partnerships is one of the industry's premier partnering meetings for pharmaceutical and biotech companies seeking partnerships in the top therapeutic areas: oncology, cardiovascular, metabolic and neurosciences. Decision-makers focusing on these therapeutic categories meet to assess the potential for strategic alliances between their companies. The conference includes company presentations, one-on-one meetings and networking functions. For information, visit http://www.tapartnerships.com/.
About Nereus Pharmaceuticals, Inc.
Nereus Pharmaceuticals pursues novel sources of chemical diversity to discover and develop new therapeutics. Using its unmatched expertise in marine microbiology to identify unique biologically active compounds, the Company has two oncology drug candidates in Phase I clinical trials. NPI-2358, a tumor vascular disrupting agent, is being evaluated in patients with solid tumors and lymphomas, and the proteasome inhibitor NPI-0052 is being developed in patients with solid tumors, lymphomas, leukemias and multiple myeloma. The Company's discovery portfolio also includes potential drug candidates for cancer, infectious diseases and inflammation. For more information, visit http://www.nereuspharm.com/.
Nereus Pharmaceuticals is a registered trademark of Nereus Pharmaceuticals, Inc. All other product and company names may be registered trademark or trademarks of their respective owners.
Nereus Pharmaceuticals, Inc.
CONTACT: Kobi M. Sethna, President & CEO of Nereus Pharmaceuticals,Inc., +1-858-587-4093, ksethna@nereuspharm.com; or Pam Lord of Porter NovelliLife Sciences, +1-619-849-6003, plord@pnlifesciences.com, for Nereus
Web site: http://www.nereuspharm.com/
Source: PRNewswire
Related Articles
- Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer
- Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
- Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
- Allos Starts Phase I Trial in Solid Tumors
- Avalon Pharmaceuticals Advances AVN944 into a Phase II Clinical Trial in Solid Tumors
- Tigris Pharmaceuticals Initiates a Multi-Center Phase II Clinical Trial of A-007 in Patients With High-Grade Cervical Intraepithelial Neoplasia (CIN)
- Somaxon Pharmaceuticals, Inc. Initiates Second Phase III Clinical Trial of SILENOR(TM) -- Product Will Be Evaluated in Long-Term Trial of Elderly Patients With Primary Chronic Insomnia
- Arena Pharmaceuticals Announces Initiation of Phase 2b Clinical Trial of Its Novel Anti-Obesity Compound
- Vertex Pharmaceuticals Announces Advancement to Phase Ib Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C
 |
 |
User Comments (0)
RSS Feeds